Histone deacetylase (HDAC) inhibitors and doxorubicin combinations target both breast cancer stem cells and non-stem breast cancer cells simultaneously.

Ling-Wei HiiFelicia Fei-Lei ChungJaslyn Sian-Siu SooBoon Shing TanChun-Wai MaiChee-Onn Leong

Published in: Breast cancer research and treatment (2019)

In conclusion, this study demonstrates the potential of HDACi as therapeutic options, either as monotherapy or in combination with chemotherapeutics against refractory breast cancer.

Keyphrases

histone deacetylase
stem cells
breast cancer cells
drug delivery
randomized controlled trial
combination therapy
cell therapy
open label
mesenchymal stem cells
clinical trial
study protocol